A Phase 1, Randomized, Controlled, Double-blind, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of AERAS-422 in Healthy Adults

Trial Profile

A Phase 1, Randomized, Controlled, Double-blind, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of AERAS-422 in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2012

At a glance

  • Drugs AERAS 422; BCG
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Aug 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
    • 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top